Outback senators

US researchers start that people with recollection problems who are depressed are at higher gamble of developing Alzheimer’s infection than people who
are not depressed, and that the lay Alzheimer’s medicine donepezil (brand name Aricept) may dally progress to Alzheimer’s in depressed people who
be dressed reminiscence problems or mild cognitive impairment (MCI).

The research was the being planned of take the lead architect Dr Po H Lu, aid professor of neurology with the David Geffen Way of life of Prescription at University of
California Los Angeles (UCLA), and colleagues, and is published online in the 16 June promulgation of Neurology, the medical scrapbook of the
American Academy of Neurology.

Lu said in a statement that:

“Our longer term findings add to the body of evidence that suggests impression is a major jeopardy factor recompense Alzheimer’s disease.”

“Since the drug donepezil has been shown to improve the behavioral symptoms of Alzheimer’s disease, our study also tested whether the analgesic would
delay the making to Alzheimer’s disease in people with memory problems,” he added.

A himself with Mild Cognitive Impairment (MCI) has problems with respect that are greater than those brought on by universal aging, but they don’t
show symptoms of Alzheimer’s such as distress completing every day activities.

For the study, Lu and colleagues followed the progress of 756 people between 55 and 91 years of age who had MCI and were taking part in a three-year, bent over-blind, placebo-controlled Alzheimer’s Disease Cooperative Study trial of donepezil and vitamin E.

A double blind thorn in the flesh is one where neither the participants nor the health professionals who make over them the drugs know whether they are taking the active drug or a placebo.

At the start of the den the participants underwent a examination that measured depression severity and intensity (the Beck Gloominess Inventory, BDI), and
208 were diagnosed with depression using the BDI.

The main outcome measure was train to possible or presumed Alzheimer’s disease, which was diagnosed either during or at the reason of the
trial.

The participants were in three goups: one troupe was given vitamin E, another donepezil and the third a placebo.

The results showed that:

• A participant’s risk of developing Alzheimer’s went up by 3 per cent for each point increase on the depression test.
• At 1.7 years into the study, among depressed-diagnosed participants with MCI, 11 per cent of those given donepezil developed Alzheimer’s disease
  compared to 25 per cent of those who were given vitamin E or placebo.
• At 2.2 years into the study, these figures went up to 14 per cent and 29 per cent respectively.
• Donepezil had little effect in the participants who were not diangosed with depression.

The authors concluded that:

“Results suggest that gloom is predictive of making from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD) and
treatment with donepezil delayed progression to AD among depressed subjects with aMCI. Donepezil appears to balance the increased endanger of AD
conferred by the presence of depressive symptoms.”

Lu said:

“If we can delay the progress of this disease due to the fact that even two years, it could significantly look up the quality of life for many people dealing with
reminiscence disappointment.”

The FDA has not approved donepezil (Aricept) for the treatment of MCI but at best for mild to moderate and stern Alzheimer’s.

Alzheimer’s infection, which is named after the German physician Alois Alzheimer who first described it in 1906, is the most common formation of
dementia, accounting for 50 to 70 per cent of cases. It is a liberal and fatal brain disease with no cure and the 7th peerless creator of cessation in the
US.

Alzheimer’s destroys brain cells, causing problems with thought, thinking and behavior that impair faculty to work, relate to others, enjoy hobbies and
get on with every heyday life. The Nationwide Alliance on Aging reports that according to brand-new estimates, as many as 2.4 to 4.5 million Americans are
living with Alzheimer’s.

“Donepezil delays progression to AD in MCI subjects with depressive symptoms.”
Lu, P. H., Edland, S. D., Teng, E., Tingus, K., Petersen, R. C., Cummings, J. L., On behalf of The Alzheimer’s Disease Cooperative Study Group.
Neurology, 2009 72: 2115-2121.
Published online 16 June 2009.

Additional sources: American Academy of Neurology, Alzheimer’s Link, NIA.

Written by: Catharine Paddock, PhD

In consideration of drug information on ARICEPT.

Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today